Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEVE UCCD: TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
jRCT2061220065Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of duvakitug in autoimmune colitis and Crohn's disease (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Clinical remission in ulcerative colitis at week 14 and Endoscopic response in Crohn's disease at week 14. Started Dec 2023; status: completed.
02
Drugs
duvakitug
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on jRCT2061220065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220065.